GlassScriptPhysician profile
Frank D Cirisano
NPI 1326030966
$113,790.72
in general payments reported to CMS, 2019-2025
40 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $7,793 · 2021: $11K · 2022: $17K · 2023: $13K · 2024: $14K · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $2,257 · Consulting Fee: $1,665 · Travel and Lodging: $1,390 · Education: $32.83 · Gift: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,755.00 |
| Food and Beverage | $2,256.90 |
| Consulting Fee | $1,665.00 |
| Travel and Lodging | $1,390.34 |
| Education | $32.83 |
| Gift | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41,788.50 | 2019-2024 | Jemperli, Zejula |
| Tesaro, INC. | $33,204.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30,013.25 | 2019-2024 | Lynparza |
| Baxter Healthcare | $2,272.50 | 2021 | |
| Mimedx Group, INC. | $2,250.28 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $1,090.84 | 2020-2024 | Myrisk |
| Merck Sharp & Dohme LLC | $415.14 | 2019-2025 | Lynparza, Keytruda |
| Coopersurgical, INC. | $409.07 | 2022-2025 | Ally II Ups, Advincula Delineator Uterine Manipulator |
| Clovis Oncology, INC. | $371.95 | 2019-2022 | |
| Intuitive Surgical, INC. | $294.44 | 2021-2023 | Da Vinci Surgical System |
| Coloplast Corp | $255.96 | 2019-2023 | Saffron |
| Biotissue Holdings INC. | $152.96 | 2023-2025 | |
| Ethicon US, LLC | $151.51 | 2019-2021 | |
| Caris Mpi, INC. | $140.61 | 2025 | Mi Cancer Seek |
| Hologic Sales and Service, LLC | $124.27 | 2019-2025 | Acessa Provu System, Fluent Fluid Management System |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $115.16 | 2019 | |
| Caldera Medical, INC | $83.75 | 2023 | Desara |
| Momentis Surgical INC. | $75.64 | 2022-2023 | Anovo Surgical System |
| Davol INC. | $55.50 | 2023-2025 | Phasix Mesh, Arista |
| Aroa Biosurgery Incorporated | $52.04 | 2024 | |
| Tactile Systems Technology INC | $43.41 | 2019-2020 | |
| Genentech USA, INC. | $42.79 | 2019 | |
| Coherus Oncology, INC. | $35.47 | 2022 | |
| Seagen INC. | $33.88 | 2021-2022 | |
| Verastem, INC. | $28.80 | 2025 | Avmapki Fakzynja Co-Pack |
| Lilly USA, LLC | $28.39 | 2023 | Retevmo |
| Janssen Biotech, INC. | $26.19 | 2022 | |
| Sun Pharmaceutical Industries INC. | $23.63 | 2022 | |
| Eisai INC. | $22.96 | 2019 | |
| Daiichi Sankyo INC. | $20.81 | 2019 | |
| Verity Pharmaceuticals INC. | $20.80 | 2022 | |
| Amgen INC. | $20.00 | 2019 | |
| Immunogen, INC. | $19.11 | 2023 | Elahere |
| Sobi, INC | $17.99 | 2022 | |
| Pfizer INC. | $16.98 | 2025 | |
| Provepharm INC. | $16.89 | 2025 | Bludigo |
| Amag Pharmaceuticals, INC. | $13.78 | 2020 | |
| Acera Surgical, INC. | $13.78 | 2023 | Restrata Wound Matrix |
| Dysis Medical, INC. | $13.37 | 2021 | |
| Solventum Corporation | $13.36 | 2024 | V.A.C. Veraflo Cleanse Choice, Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Cirisano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.